Our recent study suggests that at least in the context of gastric cancer, TLR2 antagonists can ameliorate tumour growth by acting directly on the tumour cells to promote apoptosis and suppress proliferation. However, it is important to consider that TLR agonists (including those for TLR2) can induce adaptive immune responses against cancer cells, which supports the application of TLR agonists in cancer vaccine therapy.
|Pages (from-to)||1260 - 1261|
|Number of pages||2|
|Publication status||Published - 2012|